Scientists Win $3M Prize for Gene Therapy Breakthroughs

Children who struggled to navigate obstacle courses in dim light can now walk confidently just 30 days after a groundbreaking gene therapy treatment restored their vision.

Three researchers at the University of Pennsylvania won one of science's most lucrative prizes for developing Luxturna, the first FDA-approved gene therapy that treats an inherited form of blindness. Jean Bennett, Albert Maguire, and Katherine High discovered they could inject a working copy of the RPE65 gene directly into patients' retinas using a modified virus as a delivery vehicle.

The disease affects children born with two faulty copies of the RPE65 gene. In healthy eyes, light hits a molecule that bends and straightens rapidly, enabling vision. But in these children, the molecule stays deformed, leading to blindness by adulthood.

Before treatment, study participants bumped into objects and wandered off course in low light conditions. "They greatly improved their ability to navigate," says High, describing the rapid transformation patients experienced. "It happens pretty quickly."

High learned about the prize while riding a train and had to stifle a scream to avoid disturbing fellow passengers. She plans to donate her share to charities and hospitals serving people living in poverty.

The Ripple Effect

This single treatment represents far more than one cure. Retinal neuroscientist Omar Mahroo calls Luxturna "transformative for one form of blindness that was untreatable" and describes it as a "paradigm shift that signals hope" for future gene therapies targeting other causes of blindness.

Two other life science prizes recognized equally important advances. Rosa Rademakers and Bryan Traynor independently discovered that a common genetic mutation causes both frontotemporal dementia and motor neuron disease, opening new research pathways. Stuart Orkin and Swee Lay Thein identified a gene switch that led to Casgevy, the first FDA-approved gene-editing therapy for sickle-cell disease.

Meanwhile, hundreds of physicists won a prize for measuring the magnetic properties of subatomic particles to an astonishing precision of 127 parts in a billion. Their work continues to push the boundaries of what humans can achieve through careful observation and persistence.

These breakthroughs remind us that patient, collaborative science creates real miracles for real people.